RCT: Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer.
30 Jul, 2021 | 11:43h | UTC
Commentary on Twitter
In postmenopausal women with hormone-receptor-positive breast cancer who had 5 yrs of AI, extending adjuvant endocrine therapy by 5 years provides no benefit over a 2-year extension but is associated with a greater risk of bone fracturehttps://t.co/YDxeQVu8B9
— K Pavithran (@drkpavithran) July 29, 2021